AMZ-002 is under clinical development by Amzell and currently in Phase I for Infantile Spasm (West Syndrome). According to GlobalData, Phase I drugs for Infantile Spasm (West Syndrome) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AMZ-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AMZ-002 overview

AMZ-002 is under development for the treatment of catastrophic infantile epileptic disease called infantile spasms. The drug candidate is a highly purified sterile synthetic hormone and is administered by intramuscular route. It is a repurposed drug. The drug candidate is a synthetic derivative of adrenocorticotropic hormone

Amzell overview

Amzell is a drug development company that provides common effluent treatment facilities. It is a specialist, virtual development pharmaceutical company which takes candidate or re purposed drugs and devices either through to proof of concept, or through to registration for sale to commercial healthcare companies. The company has a particular interest in developing well-characterized active substances utilizing innovative platform drug delivery technologies, which provide more effective drug delivery, increased efficacy, and improved safety and compliance. It specializes in in-licensing drug development projects and seeing them through from proof of concept to marketing authorization in important markets. Amzell is headquartered in the Netherland.

For a complete picture of AMZ-002’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.